Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
08 February 2021Website:
http://trisaluslifesci.comNext earnings report:
01 April 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | Tue, 19 Nov 2024 21:00:01 GMTDividend
Analysts recommendations
Institutional Ownership
TLSI Latest News
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today that Mary Szela, Chief Executive Officer and President of TriSalus, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024. Details for the fireside ch.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q2 2024 Earnings Call Transcript August 15, 2024 9:00 AM ET Company Participants Jim Young - SVP, IR and Treasurer Mary Szela - President and CEO Alex Kim - SVP, Interventional Radiology Steven Katz - CMO Sean Murphy - CFO Conference Call Participants Justin Walsh - JonesTrading Operator Good morning, and welcome to TriSalus Science Second Quarter 2024 Earnings Conference Call. Currently, all participants are on listen-only mode.
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the expiration and results of its previously announced exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its warrants (the “Warrants”) identified in the Prospectus/Offer to Ex.
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its warrants (the “Warrants”) identified in the Prospectus/Offer to Exchange (as defined below). The purpose of.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) will hold its Q1 2024 Earnings Conference Call on May 15, 2024 at 9:00 AM ET. Participants include Jim Young, Mary Szela, Sean Murphy, and Justin Walsh from JonesTrading. Good morning and welcome to the TriSalus Life Sciences First Quarter 2024 Earnings Conference Call.
TriSalus Life Sciences® Inc., an oncology company combining its unique delivery technology with immunotherapy to revolutionize treatment for patients with liver and pancreatic tumors, will hold a conference call and webcast on May 15, 2024, at 9:00 a.m. ET to review financial results for the first quarter ending March 31, 2024, and offer a business update. A press release with the first quarter results will be released beforehand.
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) announced today that the Company will host a conference call and webcast on April 1, 2024, at 9:00 a.m. ET to discuss financial results for the fourth quarter and full year ended December 31, 2023, and provide a business update. A press release detailing the fourth quarter and full year results will be issued prior to the call. Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Results Full financial results fo.
What type of business is TriSalus Life Sciences?
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
What sector is TriSalus Life Sciences in?
TriSalus Life Sciences is in the Healthcare sector
What industry is TriSalus Life Sciences in?
TriSalus Life Sciences is in the Medical Devices industry
What country is TriSalus Life Sciences from?
TriSalus Life Sciences is headquartered in United States
When did TriSalus Life Sciences go public?
TriSalus Life Sciences initial public offering (IPO) was on 08 February 2021
What is TriSalus Life Sciences website?
https://trisaluslifesci.com
Is TriSalus Life Sciences in the S&P 500?
No, TriSalus Life Sciences is not included in the S&P 500 index
Is TriSalus Life Sciences in the NASDAQ 100?
No, TriSalus Life Sciences is not included in the NASDAQ 100 index
Is TriSalus Life Sciences in the Dow Jones?
No, TriSalus Life Sciences is not included in the Dow Jones index
When was TriSalus Life Sciences the previous earnings report?
No data
When does TriSalus Life Sciences earnings report?
The next expected earnings date for TriSalus Life Sciences is 01 April 2025